Leerink Partners starts Eloxx Pharma coverage with Outperform
Leerink Partners initiated coverage of Eloxx Pharma with an Outperform rating and a $32.00 price target, implying 82.3% upside from the Sep 17 close of $17.55.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.